Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis

Renal Failure

Volumn 33, Issue 2, 2011, Pages 118-123

  Roozbeh, Jamshid ^a   Shahriyari, Bahram ^a   Akmali, Masoumeh ^b   Vessal, Ghazal ^b   Pakfetrat, Maryam ^a   Jalali, Ghanbar Ali Raees ^a   Afshariani, Raha ^b   Hasheminasab, Mahshid ^a   Ghahramani, Nasrollah ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

anemia; hemodialysis; oxidative stress; silymarin; vitamin E

Indexed keywords

ALPHA TOCOPHEROL; BIOLOGICAL MARKER; GLUTATHIONE PEROXIDASE; HEMOGLOBIN; MALONALDEHYDE; SILYMARIN;

ADULT; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

ADULT; ANTIOXIDANTS; ATHEROSCLEROSIS; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; GLUTATHIONE PEROXIDASE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; SILYMARIN; VITAMIN E;

EID: 79951979244     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.541579     Document Type: Article

References (43)

1. Locatelli F, Del Vecchio L, Manzoni C. Morbidity and mortality on maintenance haemodialysis. Nephron. 1998;80(4): 380-400. (Pubitemid 28554685)
2. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290(13):697-701.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl. 3):S112-S119. (Pubitemid 28527268)
4. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens. 2003;12(6):593-598. (Pubitemid 38186749)
5. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5):1899-1911. (Pubitemid 29197978)
6. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int. 1994;45(3):876-883. (Pubitemid 24094502)
7. Galle J, Seibold S, Wanner C. Inflammation in uremic patients: What is the link? Kidney Blood Press Res. 2003;26(2): 65-75. (Pubitemid 36677061)
8. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 2007;72(9): 1149-1156. (Pubitemid 47609043)
9. Haklar G, Yegenaga I, Yalcin AS. Evaluation of oxidant stress in chronic hemodialysis patients: Use of different parameters. Clin Chim Acta. 1995;234(1-2):109-114.
10. Jackson P, Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem. 1995;41(8 Pt 1): 1135-1138.
11. Loughrey CM, Young IS, Kightbody JH, et al. Oxidative stress in haemodialysis. QJM. 1994;87(11):679-683.
12. Homsi E, de Brito SM, Janino P. Silymarin exacerbates p53-mediated tubular apoptosis in glycerol-induced acute kidney injury in rats. Ren Fail. 2010;32(5):623-632.
13. Tunca R, Sozmen M, Citil M, Karapehlivan M, Erginsoy S, Yapar K. Pyridine induction of cytochrome P450 1A1, iNOS and metallothionein in Syrian hamsters and protective effects of silymarin. Exp Toxicol Pathol. 2009;61(3):243-255.
14. Senturk H, Kabay S, Bayramoglu G. Silymarin attenuates the renal ischemia/reperfusion injury-induced morphological changes in the rat kidney. World J Urol. 2008;26(4): 401-407.
15. Varzi HN, Esmailzadeh S, Morovvati H, Avizeh R, Shahriari A, Givi ME. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther. 2007;30(5):477-481. (Pubitemid 47366620)
16. Kaur G, Athar M, Alam MS. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. Invest New Drugs. 2010;28(5):703-713.
17. Soto C, Pérez J, García V, Uría E, Vadillo M, Raya L. Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine. 2010;17(14):1090-1094. Epub 2010 Jun 25.
18. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006;124(5):491-504. (Pubitemid 46157708)
19. Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther. 1999;290(3):1375-1383. (Pubitemid 29400283)
20. Dietzmann J, Thiel U, Ansorge S, Neumann KH, Täger M. Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy. Free Radic Biol Med. 2002;33(10): 1347-1354. (Pubitemid 35284919)
21. Kren V, Walterova D. Silybin and silymarin - New effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005;149(1):29-41.
22. Zal F, Mostafavi-Pour Z, Vessal M. Comparison of the effects of vitamin E and/or quercetin in attenuating chronic cyclosporine A-induced nephrotoxicity in male rats. Clin Exp Pharmacol Physiol. 2007;34(8):720-724. (Pubitemid 47013484)
23. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70(1):158-169.
24. Giray B, Kan E, Bali M, Hincal F, Basaran N. The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta. 2003;338(1-2):91-98. (Pubitemid 37456695)
25. Uzum A, Toprak O, Gumustas MK, Ciftci S, Sen S. Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis. J Nephrol. 2006;19(6):739-745. (Pubitemid 46415978)
26. Bayes B, Pastor MC, Bonal J, Juncà J, Romero R. Homocysteine and lipid peroxidation in haemodialysis: Role of folinic acid and vitamin E. Nephrol Dial Transplant. 2001;16(11): 2172-2175. (Pubitemid 33062139)
27. Cristol JP, Bose JY, Badiou S, et al. Erythropoietin and oxidative stress in haemodialysis: Beneficial effects of vitamin E supplementation. Nephrol Dial Transplant. 1997;12(11): 2312-2317. (Pubitemid 27474613)
28. Giardini O, Taccone-Gallucci M, Lubrano R, et al. Evidence of red blood cell membrane lipid peroxidation in haemodialysis patients. Nephron. 1984;36(4):235-237. (Pubitemid 14192563)
29. Durmaz R, Inal M, Angin K, Atasoy MA, Altinisik M, Tel E. The effects of MK-801 and U-83836E on post-ischemic reperfusion injury in rat brain. Acta Neurobiol Exp (Wars). 1999;59(2):99-104. (Pubitemid 29292749)
30. Miguel A, Miguel A, Linares M . Evidence of an increased susceptibility to lipid peroxidation in red blood cells of chronic renal failure patients. Nephron. 1988;50(1):64-65.
31. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis. 2000;150(1):217-224.
32. Antoniadi G, Eleftheriadis T, Liakopoulos V, et al. Effect of one-year oral alpha-tocopherol administration on the antioxidant defense system in hemodialysis patients. Ther Apher Dial. 2008;12(3):237-242. (Pubitemid 351743606)
33. Galli F, Rovidati S, Chiarantini L, Campus G, Canestrari F, Buoncristiani U. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int. 1998;54(2):580-589. (Pubitemid 28357422)
34. Galli F, Varga Z, Balla J, et al. Vitamin E, lipid profile, and peroxidation in hemodialysis patients. Kidney Int Suppl. 2001;78:S148-S154. (Pubitemid 32144088)
35. Huseini HF, Larijani B, Heshmat R, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: A randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006;20(12):1036-1039. (Pubitemid 44951705)
36. Eaton JW, Leida MN. Hemolysis in chronic renal failure. Semin Nephrol. 1985;5(2):133-139.
37. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal disease patients: A potential component of hemodialysis-associated inflammation. Hemodial Int. 2005;9(1): 37-46. (Pubitemid 40932774)
38. Jacob HS, Eaton JW, Yawata Y, Shortened red blood cell survival in uremic patients: Beneficial and deleterious effects of dialysis. Kidney Int Suppl. 1975;2:139-143.
39. Eschbach JW. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989;35(1):134-148. (Pubitemid 19047434)
40. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985;28(1):1-5. (Pubitemid 15023016)
41. Wu SG, Jeng FR, Wei SY, et al. Red blood cell osmotic fragility in chronically hemodialyzed patients. Nephron. 1998;78(1): 28-32.
42. Usberti M, Gerardi G, Micheli A, et al. Effects of a vitamin Ebonded membrane and of glutathione on anemia and erythropoietin requirements in hemodialysis patients. J Nephrol. 2002;15(5): 558-564. (Pubitemid 35396521)
43. Usberti M, Lima G, Arisi M, Bufano G, D'Avanzo L, Gazzotti RM. Effect of exogenous reduced glutathione on the survival of red blood cells in hemodialyzed patients. J Nephrol. 1997;10(5):261-265. (Pubitemid 27465861)